Literature DB >> 21969260

Radiation-induced tumor neoantigens: imaging and therapeutic implications.

Christopher D Corso1, Arif N Ali, Roberto Diaz.   

Abstract

Exposure of tumor cells to ionizing radiation (IR) is widely known to induce a number of cellular changes. One way that IR can affect tumor cells is through the development of neoantigens which are new molecules that tumor cells express at the cell membrane following some insult or change to the cell. There have been numerous reports in the literature of changes in both tumor and tumor vasculature cell surface molecule expression following treatment with IR. The usefulness of neoantigens for imaging and therapeutic applications lies in the fact that they are differentially expressed on the surface of irradiated tumor cells to a greater extent than on normal tissues. This differential expression provides a mechanism by which tumor cells can be "marked" by radiation for further targeting. Drug delivery vehicles or imaging agents conjugated to ligands that recognize and interact with the neoantigens can help to improve tumor-specific targeting and reduce systemic toxicity with cancer drugs. This article provides a review of the molecules that have been reported to be expressed on the surface of tumor cells in response to IR either in vivo or in vitro. Additionally, we provide a discussion of some of the methods used in the identification of these antigens and applications for their use in drug delivery and imaging.

Entities:  

Year:  2011        PMID: 21969260      PMCID: PMC3180059     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  159 in total

1.  Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors.

Authors:  Ralph J Passarella; Daniel E Spratt; Alice E van der Ende; John G Phillips; Hongmei Wu; Vasanth Sathiyakumar; Li Zhou; Dennis E Hallahan; Eva Harth; Roberto Diaz
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

2.  Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.

Authors:  Laurence Zitvogel; Oliver Kepp; Laura Senovilla; Laurie Menger; Nathalie Chaput; Guido Kroemer
Journal:  Clin Cancer Res       Date:  2010-04-26       Impact factor: 12.531

Review 3.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

4.  Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting.

Authors:  Marcel Janssen; Wim J G Oyen; Leon F A G Massuger; Cathelijne Frielink; Ingrid Dijkgraaf; D Scott Edwards; Milind Radjopadhye; Frans H M Corstens; Otto C Boerman
Journal:  Cancer Biother Radiopharm       Date:  2002-12       Impact factor: 3.099

Review 5.  Locally advanced non-small cell lung cancer: the past, present, and future.

Authors:  Ramaswamy Govindan; Jeffrey Bogart; Everett E Vokes
Journal:  J Thorac Oncol       Date:  2008-08       Impact factor: 15.609

6.  Changed adhesion molecule profile of Ewing tumor cell lines and xenografts under the influence of ionizing radiation.

Authors:  Stefan Könemann; Johann Malath; Tobias Bölling; Astrid Kolkmeyer; Kirsten Janke; Dorothea Riesenbeck; Stefan Hesselmann; Tan Phu Nguyen; Raihanatou Diallo; Josef Vormoor; Normann Willich; Andreas Schuck
Journal:  Anticancer Res       Date:  2004 May-Jun       Impact factor: 2.480

7.  Radiation-guided drug delivery to tumor blood vessels results in improved tumor growth delay.

Authors:  Ling Geng; Katherine Osusky; Sekhar Konjeti; Allie Fu; Dennis Hallahan
Journal:  J Control Release       Date:  2004-10-19       Impact factor: 9.776

8.  Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.

Authors:  Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

9.  Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Authors:  Andres Forero; Paul L Weiden; Julie M Vose; Susan J Knox; Albert F LoBuglio; Jordan Hankins; Michael L Goris; Vincent J Picozzi; Don B Axworthy; Hazel B Breitz; Robert B Sims; Richard G Ghalie; Sui Shen; Ruby F Meredith
Journal:  Blood       Date:  2004-03-02       Impact factor: 22.113

10.  In vivo99mTc-HYNIC-annexin V imaging of early tumor apoptosis in mice after single dose irradiation.

Authors:  Ming-fang Guo; Yaqing Zhao; Rong Tian; Lin Li; Leiming Guo; Feng Xu; Yong-mei Liu; Yong-bo He; Sen Bai; Jin Wang
Journal:  J Exp Clin Cancer Res       Date:  2009-10-08
View more
  22 in total

Review 1.  Gene therapy for radioprotection.

Authors:  W H Everett; D T Curiel
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

2.  P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.

Authors:  Yosi Shamay; Moshe Elkabets; Hongyan Li; Janki Shah; Samuel Brook; Feng Wang; Keren Adler; Emily Baut; Maurizio Scaltriti; Prakrit V Jena; Eric E Gardner; John T Poirier; Charles M Rudin; José Baselga; Adriana Haimovitz-Friedman; Daniel A Heller
Journal:  Sci Transl Med       Date:  2016-06-29       Impact factor: 17.956

Review 3.  Recent advances and future of immunotherapy for glioblastoma.

Authors:  Neha Kamran; Alexandra Calinescu; Marianela Candolfi; Mayuri Chandran; Yohei Mineharu; Antonela S Asad; Carl Koschmann; Felipe J Nunez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2016-07-27       Impact factor: 4.388

4.  Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal cancer.

Authors:  Allison N DuRoss; Madeleine R Landry; Charles R Thomas; Megan J Neufeld; Conroy Sun
Journal:  Cancer Lett       Date:  2020-11-21       Impact factor: 9.756

5.  Ipilimumab and radiation therapy for melanoma brain metastases.

Authors:  Ann W Silk; Michael F Bassetti; Brady T West; Christina I Tsien; Christopher D Lao
Journal:  Cancer Med       Date:  2013-10-10       Impact factor: 4.452

Review 6.  Radiation meets immunotherapy - a perfect match in the era of combination therapy?

Authors:  Klara Soukup; Xinhui Wang
Journal:  Int J Radiat Biol       Date:  2015-02-09       Impact factor: 2.694

Review 7.  No patient left behind: The promise of immune priming with epigenetic agents.

Authors:  Corey A Carter; Bryan T Oronsky; Joseph Roswarski; Arnold L Oronsky; Neil Oronsky; Jan Scicinski; Harry Lybeck; Michelle M Kim; Michelle Lybeck; Tony R Reid
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

Review 8.  Turning 'Cold' tumors 'Hot': immunotherapies in sarcoma.

Authors:  Jeff Rytlewski; Mohammed M Milhem; Varun Monga
Journal:  Ann Transl Med       Date:  2021-06

9.  PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes.

Authors:  Shisuo Du; Lin Zhou; Gregory S Alexander; Kyewon Park; Lifeng Yang; Nadan Wang; Nicholas G Zaorsky; Xinliang Ma; Yajing Wang; Adam P Dicker; Bo Lu
Journal:  J Thorac Oncol       Date:  2017-12-13       Impact factor: 20.121

10.  Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy.

Authors:  Gregory S Alexander; Joshua D Palmer; Madalina Tuluc; Jianqing Lin; Adam P Dicker; Voichita Bar-Ad; Larry A Harshyne; Jennifer Louie; Colette M Shaw; D Craig Hooper; Bo Lu
Journal:  J Hematol Oncol       Date:  2016-09-23       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.